Bill Text: IL HB4055 | 2023-2024 | 103rd General Assembly | Enrolled

NOTE: There are more recent revisions of this legislation. Read Latest Draft

---

Bill Title: Amends the Prior Authorization Reform Act. Provides that notwithstanding any other provision of law, a health insurance issuer or a contracted utilization review organization may not require a prior authorization for drug therapies approved by the U.S. Food and Drug Administration for the treatment of hereditary bleeding disorders any more frequently than 6 months or the length of time the prescription for that dosage remains valid, whichever period is shorter. Effective January 1, 2026.

Spectrum: Moderate Partisan Bill (Republican 9-1)

Status: (Passed) 2024-07-19 - Public Act . . . . . . . . . 103-0659 [HB4055 Detail]

Download: Illinois-2023-HB4055-Enrolled.html

---

HB4055 Enrolled LRB103 31972 BMS 60758 b
AN ACT concerning regulation.
Be it enacted by the People of the State of Illinois,
represented in the General Assembly:
Section 5. The Prior Authorization Reform Act is amended
by adding Section 77 as follows:
(215 ILCS 200/77 new)
Sec. 77. Prior authorization for drug therapies for
hereditary bleeding disorders. Notwithstanding any other
provision of law, a health insurance issuer or a contracted
utilization review organization may not require a prior
authorization for drug therapies approved by the U.S. Food and
Drug Administration for the treatment of hereditary bleeding
disorders any more frequently than 6 months or the length of
time the prescription for that dosage remains valid, whichever
period is shorter.